Live Breaking News & Updates on ஆராய்ச்சி தேசிய ப்ரையாரிடீ|Page 1

Stay updated with breaking news from ஆராய்ச்சி தேசிய ப்ரையாரிடீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy


Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy
March 5, 2021 GMT
The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients
Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups
Decision has no impact on ABX464 development in chronic inflammatory indications
ABX464 top-line clinical data expected in Q2 2021 for phase 2b ulcerative colitis trial and phase 2a rheumatoid arthritis trial ....

United States , France General , Eric Cua , Chris Maggos , Regina Jehle , Enregistrement Universel , Marion Janic , Ghislaine Gasparetto , Anne Hennecke , Hartmutj Ehrlich , Jorge Kalil , Mc Services , Research National Priority , Rooney Partners , Relations Investors Europe , University Hospital Center , Data Safety , Monitoring Board , Euronext Paris , Clinical Immunology , French Autorit , Des March , Corporate News , Drug Trials , Products And Services , Health Care Industry ,

Investegate |ABIVAX Announcements | ABIVAX: Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy


ABIVAX
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
DGAP-News: ABIVAX
/ Key word(s): Study
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
05.03.2021 / 20:00
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial 
due to lack of efficacy
The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients
Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups
Decision has no impact on ABX464 development in chronic inflammatory indications ....

France General , Eric Cua , Hartmutj Ehrlich , Jorge Kalil , Research National Priority , University Hospital Center , Data Safety , Monitoring Board , Euronext Paris , Clinical Immunology , Investegate Announcements , Investegate Company Announcements , Eqs And , பிரான்ஸ் ஜநரல் , எரிக் சுய , ஜார்ஜ் கலில் , ஆராய்ச்சி தேசிய ப்ரையாரிடீ , பல்கலைக்கழகம் மருத்துவமனை மையம் , தகவல்கள் பாதுகாப்பு , கண்காணிப்பு பலகை , மருத்துவ நோயெதிர்ப்பு , ஈக்ஸ் மற்றும் ,

Inotrem's COVID-19 Phase IIa Clinical Trial Declared "National Priority Research" by the French Government's Clinical Trial Council


Press release content from Business Wire. The AP news staff was not involved in its creation.
Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council
December 24, 2020 GMT
PARIS (BUSINESS WIRE) Dec 24, 2020
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET). ....

United States , Jean Jacques Garaud , Research National Priority , National Priority Research , Roche Group , Scientific Council , French Ethics Committee , Jacques Garaud , North American , Business Wire , Products And Services , Coronavirus Pandemic , Product Testing , Health Care Industry , Lung Disease , Medical Biotechnology Industry , Medical Research , Clinical Trials , Western Europe , Infectious Diseases , Corporate News , North America , Diseases And Conditions , Government And Politics , ஒன்றுபட்டது மாநிலங்களில் , ஜீன் ஜாக்ஸ் காரௌத் ,

Investegate |ABIVAX Announcements | ABIVAX: Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council


ABIVAX
Abivax s Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government s Clinical Trial Council
DGAP-News: ABIVAX
/ Key word(s): Study
Abivax s Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government s Clinical Trial Council
22.12.2020 / 19:30
The issuer is solely responsible for the content of this announcement.
Abivax s Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government s Clinical Trial Council
Research National Priority has priority for patient enrollment in clinical trials for an accelerated review and approval process with the French regulatory authorities
Effective Covid-19 treatments very much needed because optimal vaccination coverage of millions of individuals and public acceptance will take time ....

United States , France General , Abivax Covid , Hartmutj Ehrlich , Philippe Pouletty , Research National Priority , Clinical Trial Council , Scientific Council , Clinical Trial , National Priority , Euronext Paris , French Ethics , Truffle Capital , Latin American , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஆராய்ச்சி தேசிய ப்ரையாரிடீ , மருத்துவ சோதனை சபை , அறிவியல் சபை , மருத்துவ சோதனை , தேசிய ப்ரையாரிடீ , பிரஞ்சு நெறிமுறைகள் , உணவு பண்டமாற்று மூலதனம் , லத்தீன் அமெரிக்கன் ,